← All stocks

bioAffinity Technologies, Inc.

BIAF Balanced
CIK 0001712762 #5518 in the set updated 17 Sep 2026
Bought (120 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

15 insiders · 40 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Anderson Robert A.
Director
(1)
$0.00
163,936
DIAMOND STUART
Director
(1)
$0.00
99,088
Edwards James Michael
VP and CFO
(1)
$0.00
120,128
+2,028%
GIRGENTI STEVEN
Executive Chairman
(1)
$0.00
1,089,017
+393.0%
KNIGHT PETER S
Director
(1)
$0.00
117,455
+722.2%
Rubin Gary D
Director
(1)
$0.00
1,714,415
+105.2%
Zannes Maria
President & CEO
(1)
$0.00
280,359
+7,751%
Perlmutter Nathan M
10% owner
327,909
+97.4%
Meghji Mohsin Y
Director
109,737
+284.1%
Dougherty Michael Philip
Chief Financial Officer
84,203
Joyce Roby
Director
66,615
Zannes Timothy P
Secretary, EVP, Gen. Counsel
54,765
Platt Jamie
Director
54,748
Rebel Vivienne I
Chief Sci. & Med. Officer, EVP
46,228
+547.3%
Reveles Xavier Trinidad
Chief Operating Officer
41,943
+1,059%

No percentages here. This company's share count has moved by a factor of 6.3 over the window, from 4,498,675 to 28,468,612 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 62
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 7
Shares from compensation/vesting 3,174,458
History held since 21 Oct 2022